Free Trial

OnKure Therapeutics (OKUR) Competitors

OnKure Therapeutics logo
$2.31 -0.06 (-2.53%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.37 +0.06 (+2.38%)
As of 07/25/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKUR vs. NKTX, FATE, MCRB, GNLX, FTLF, TARA, KRRO, SKYE, ACTU, and ALTS

Should you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Nkarta (NKTX), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Genelux (GNLX), FitLife Brands (FTLF), Protara Therapeutics (TARA), Korro Bio (KRRO), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry.

OnKure Therapeutics vs. Its Competitors

Nkarta (NASDAQ:NKTX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Nkarta has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Nkarta's return on equity of -26.64% beat OnKure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NkartaN/A -26.64% -21.62%
OnKure Therapeutics N/A -49.13%-45.72%

Nkarta currently has a consensus price target of $14.33, suggesting a potential upside of 563.58%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 1,299.71%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Nkarta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nkarta
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.13
OnKure Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.33

Nkarta is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/A-$108.79M-$1.51-1.43
OnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.44

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 8.4% of Nkarta shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nkarta had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Nkarta and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Nkarta's score of 0.86 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Nkarta Positive
OnKure Therapeutics Very Positive

Summary

Nkarta beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OKUR vs. The Competition

MetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$32.02M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-0.4421.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book0.308.378.665.87
Net Income-$52.67M-$55.19M$3.25B$258.55M
7 Day Performance-0.86%5.88%4.22%3.73%
1 Month Performance-8.33%17.33%10.51%11.75%
1 Year PerformanceN/A4.42%34.40%18.03%

OnKure Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OKUR
OnKure Therapeutics
3.4005 of 5 stars
$2.31
-2.5%
$32.33
+1,299.7%
N/A$32.02MN/A-0.44N/APositive News
NKTX
Nkarta
1.768 of 5 stars
$1.89
+3.3%
$14.33
+658.4%
-68.7%$134.11MN/A-1.25140Positive News
FATE
Fate Therapeutics
3.6909 of 5 stars
$1.14
-0.9%
$3.83
+236.3%
-77.0%$130.64M$13.63M-0.77550
MCRB
Seres Therapeutics
3.5129 of 5 stars
$14.85
+18.1%
$73.67
+396.1%
-46.6%$129.64M$126.32M-3.23330Positive News
High Trading Volume
GNLX
Genelux
1.2346 of 5 stars
$3.38
-1.5%
$17.75
+425.1%
+74.0%$127.54MN/A-3.8410Analyst Forecast
Gap Up
FTLF
FitLife Brands
4.0839 of 5 stars
$13.09
+0.5%
$20.50
+56.6%
-23.6%$122.92M$64.47M15.5820News Coverage
Positive News
Gap Down
TARA
Protara Therapeutics
2.1594 of 5 stars
$3.16
+3.6%
$20.50
+548.7%
+45.4%$121.91MN/A-1.8430
KRRO
Korro Bio
1.7879 of 5 stars
$12.97
+2.0%
$102.43
+689.7%
-69.4%$121.79M$2.27M-1.3770News Coverage
Analyst Forecast
SKYE
Skye Bioscience
2.5361 of 5 stars
$3.93
-1.3%
$16.60
+322.4%
-33.7%$121.73MN/A-4.7911News Coverage
Gap Up
ACTU
Actuate Therapeutics
2.252 of 5 stars
$6.20
+1.0%
$20.50
+230.6%
N/A$121.64MN/A0.0010News Coverage
ALTS
ALT5 Sigma
0.1039 of 5 stars
$6.96
-11.7%
N/A+254.0%$121.45M$12.53M0.00170

Related Companies and Tools


This page (NASDAQ:OKUR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners